Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:55 PM
Ignite Modification Date:
2025-12-24 @ 3:55 PM
NCT ID:
NCT00617292
Eligibility Criteria:
Inclusion Criteria:
For all participants:
* English-speaking
* Has undergone DNA testing for mutations in the CYP21A2 gene
For children who received prenatal dexamethasone treatment:
* Genetic confirmation of 21OHD diagnosis
* Received full or partial prenatal dexamethasone treatment
For children in the control group:
* Did not receive prenatal dexamethasone treatment
For mothers:
* History of at-risk pregnancy for a fetus affected with 21OHD
* Genetic confirmation of child's diagnosis
Exclusion Criteria:
* Any mental disorder that could prevent understanding of study materials
* Current or past steroid use for reasons other than CAH (i.e., asthma, lupus, rheumatoid arthritis)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT00617292
Study Brief:
Protocol Section:
NCT00617292